دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Is intestinal permeability increased in obesity? A review including the effects of dietary, pharmacological and surgical interventions on permeability and the microbiome
Michael Camilleri MD,Â
doi : 10.1111/dom.14899
Rationale and design of the phase 3a development programme (ONWARDS 1–6 trials) investigating once-weekly insulin icodec in diabetes
Athena Philis-Tsimikas MD,
doi : 10.1111/dom.14871
To describe the phase 3a ONWARDS clinical development programme investigating insulin icodec (icodec), a once-weekly basal insulin, including the design and rationale for each of the ONWARDS 1–6 trials.
Impact of iron supplementation on gestational diabetes mellitus: A literature review
Lulu Liu BS, Feng Yan BS, Hongyuan Yan PhD, Zhiqiang Wang PhD,
doi : 10.1111/dom.14886
Gestational diabetes mellitus (GDM) is a common complication of pregnancy, affecting 14% of pregnancies worldwide, and the prevention of pathological hyperglycaemia during pregnancy is meaningful for global public health.
Canagliflozin reduces proteinuria by targeting hyperinsulinaemia in diabetes patients with heart failure: A post hoc analysis of the CANDLE trial
Satoshi Yamaguchi MD, Michio Shimabukuro MD, Atsushi Tanaka MD, Takumi Imai PhD, Shinya Hiramitsu MD, Naohiko Takahashi MD, Toshiaki Kadokami MD, Masayoshi Ajioka MD, Makoto Suzuki MD, Koichi Node MD, on behalf of the CANDLE Trial Investigators ,Â
doi : 10.1111/dom.14876
To investigate factors associated with proteinuria regression in patients with type 2 diabetes mellitus (T2DM) treated with canagliflozin.
Non-alcoholic fatty liver disease and complications in type 1 and type 2 diabetes: A Mendelian randomization study
Ningyuan Liu MD, Ge Wang MD, Chao Liu MD, Jiayi Liu MD, Shengyuan Huang MD, Yong Zhou MD, Enhua Xiao PhD,Â
doi : 10.1111/dom.14877
To investigate the potential causal relationship between non-alcoholic fatty liver disease (NAFLD) and complications in type 1 diabetes (T1D) and type 2 diabetes (T2D).
Factors associated with successful weight loss after liraglutide treatment for obesity
Wassel Sannaa MBBS, Saam Dilmaghani MD, Joelle BouSaba MD, Daniel Maselli MD, Jessica Atieh MD, Deborah Eckert RN, Ann L. Taylor CCRP, W. Scott Harmsen MS, Andres Acosta MD, Michael Camilleri MD,Â
doi : 10.1111/dom.14880
To identify patient factors, including gastrointestinal functions, that are predictive or associated with weight loss in response to once-daily 3 mg liraglutide administered subcutaneously (SQ) or placebo in obesity.
Cost-utility analysis of semaglutide for type 2 diabetes after its addition to the National Medical Insurance System in China
Shanshan Hu MPharm, Shengying Gu PharmD, Chendong Qi MPharm, Shuowen Wang PharmD, Fengdan Qian MPharm, Chenyang Shi PharmD, Guorong Fan PharmD,Â
doi : 10.1111/dom.14881
The main research purpose is to compare the long-term cost-effectiveness of semaglutide (SEMA) with that of dulaglutide (DULA) for patients with inadequately controlled type 2 diabetes throughout their lifetime. If necessary, the second aim is to investigate a further price cut for SEMA to provide sound advice for government drug price adjustments.
Change in pharmacodynamic variables following once-weekly tirzepatide treatment versus dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono substudy)
Daisuke Yabe MD, Dan Kawamori MD, Yusuke Seino MD, Tomonori Oura MSc, Masakazu Takeuchi PhD,Â
doi : 10.1111/dom.14882
To evaluate the pharmacodynamic effects of tirzepatide, a novel dual glucagon-like peptide-1 receptor and glucose-dependent insulinotropic polypeptide receptor agonist, compared with dulaglutide in patients with type 2 diabetes.
Finerenone in patients across the spectrum of chronic kidney disease and type 2 diabetes by glucagon-like peptide-1 receptor agonist use
Peter Rossing MD, Rajiv Agarwal MD, Stefan D. Anker MD, Gerasimos Filippatos MD, Bertram Pitt MD, Luis M. Ruilope MD, Vivian Fonseca MD, Guillermo E. Umpierrez MD, Maria Luiza Caramori MD, Amer Joseph MBBS, Marc Lambelet Dipl. Math, Robert Lawatscheck MD, George L. Bakris MD, on behalf of the FIDELIO-DKD and FIGARO-DKD Investigators ,Â
doi : 10.1111/dom.14883
To explore the modifying effect of glucagon-like peptide-1 receptor agonist (GLP-1RA) use on outcomes with finerenone across a wide spectrum of patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) in the pooled analysis of FIDELIO-DKD and FIGARO-DKD.
The impact of family history of type 2 diabetes on clinical heterogeneity in idiopathic type 1 diabetes
Yan Chen MD, Qianrong Wang MD, Zhiguo Xie PhD, Gan Huang MS, Li Fan BSN, Xia Li MD, Zhiguang Zhou MD,Â
doi : 10.1111/dom.14884
To investigate the impact of family history of type 2 diabetes (T2D) on the clinical phenotypes of patients with idiopathic type 1 diabetes (T1D).
Pioglitazone reduces epicardial fat and improves diastolic function in patients with type 2 diabetes
Alexander J. Moody PhD, Marjorie Molina-Wilkins MD, Geoffrey D. Clarke PhD, Aurora Merovci MD, Carolina Solis-Herrera MD, Eugenio Cersosimo MD, Robert J. Chilton DO, Patricia Iozzo MD, Amalia Gastaldelli PhD, Muhammad Abdul-Ghani MD, Ralph A. DeFronzo MD,Â
doi : 10.1111/dom.14885
To examine the effect of pioglitazone on epicardial (EAT) and paracardial adipose tissue (PAT) and measures of diastolic function and insulin sensitivity in patients with type 2 diabetes mellitus (T2DM).
Cardiovascular risk and lifetime benefit from preventive treatment in type 2 diabetes: A post hoc analysis of the CAPTURE study
Helena Bleken Østergaard MD, Valerie Humphreys BA, Ellen Margo Hengeveld MD, Julie Broe Honoré MD, François Mach MD, Frank L. J. Visseren MD, Jan Westerink MD, Gourav Yadav MD, Ofri Mosenzon MD, on behalf of the CAPTURE investigators ,Â
doi : 10.1111/dom.14887
To assess the potential gain in the number of life-years free of a (recurrent) cardiovascular disease (CVD) event with optimal cardiovascular risk management (CVRM) and initiation of glucose-lowering agents with proven cardiovascular benefit in people with type 2 diabetes (T2D).
Effects of glucose-lowering agents on cardiovascular and renal outcomes in subjects with type 2 diabetes: An updated meta-analysis of randomized controlled trials with external adjudication of events
Edoardo Mannucci MD, Marco Gallo MD, Andrea Giaccari MD, Riccardo Candido MD, Basilio Pintaudi MD, Giovanni Targher MD, Matteo Monami MD, on behalf of the SID-AMD joint panel for Italian Guidelines on Treatment of Type 2 Diabetes ,Â
doi : 10.1111/dom.14888
To investigate the effects of glucose-lowering agents on all-cause mortality, and cardiovascular and renal outcomes in adults with type 2 diabetes.
Age-specific associations between the number of co-morbidities, all-cause mortality and public direct medical costs in patients with type 2 diabetes: A retrospective cohort study
Sabrina Nan Hong, Ivy Lynn Mak PhD, Weng Yee Chin MD, Esther Yee Tak Yu MBBS, Emily Tsui Yee Tse MBBS, Julie Yun Chen MD, Carlos King Ho Wong PhD, David Vai Kiong Chao MBChB, Wendy Wing Sze Tsui MBChB, Cindy Lo Kuen Lam MD, Eric Yuk Fai Wan PhD,Â
doi : 10.1111/dom.14889
To evaluate the association between the number of co-morbidities, all-cause mortality and public health system expenditure in patients with type 2 diabetes (T2D) across different age groups.
Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses
Mikhail N. Kosiborod MD, Meena Bhatta MD, Melanie Davies MD, John E. Deanfield MD, W. Timothy Garvey MD, Usman Khalid PhD, Robert Kushner MD, Domenica M. Rubino MD, Niels Zeuthen MSc, Subodh Verma PhD,Â
doi : 10.1111/dom.14890
Evaluate the effects of once-weekly subcutaneous semaglutide 2.4 mg on cardiometabolic risk factors in people with overweight/obesity without diabetes in the STEP 1 and 4 trials.
Effect of faecal microbial transplant via colonoscopy in patients with severe obesity and insulin resistance: A randomized double-blind, placebo-controlled Phase 2 trial
Yasaman Ghorbani BSc, Katherine J. P. Schwenger PhD, Divya Sharma PhD, Hyejung Jung MSc, Jitender Yadav PhD, Wei Xu PhD, Wendy Lou PhD, Susan Poutanen MD, Susy S. Hota MD, Elena M. Comelli PhD, Dana Philpott PhD, Timothy D. Jackson MD, Allan Okrainec MD, Herbert Y. Gaisano MD, Johane P. Allard MD,Â
doi : 10.1111/dom.14891
To assess the effects of faecal microbial transplant (FMT) from lean people to subjects with obesity via colonoscopy.
Once-weekly semaglutide versus insulin aspart for the treatment of type 2 diabetes in the UK: A long-term cost-effectiveness analysis based on SUSTAIN 11
Marc Evans MD, Barrie Chubb MSc, Samuel J. P. Malkin MSc, Sasha Berry MSc, Jack Lawson MBBS, Barnaby Hunt MSc,Â
doi : 10.1111/dom.14892
To evaluate the long-term cost-effectiveness of once-weekly semaglutide 1 mg versus insulin aspart in the UK.
Sodium-glucose co-transporter-2 inhibitors in type 2 diabetes: Are clinical trial benefits for heart failure reflected in real-world clinical practice? A systematic review and meta-analysis of observational studies
William Hinton MSc, Abdus Samad Ansari FRCOphth, Martin B. Whyte PhD, Andrew P. McGovern MD, Michael D. Feher MD, Neil Munro DPhil, Simon de Lusignan MD,Â
doi : 10.1111/dom.14893
To determine the absolute risk reduction (ARR) of heart failure events in people treated with sodium-glucose co-transporter-2 (SGLT2) inhibitors.
Changes in racial and ethnic disparities in glucose-lowering drug utilization and glycated haemoglobin A1c in US adults with diabetes: 2005-2018
Piaopiao Li MS, Ping Zhang PhD, Dawei Guan MD, Jingchuan Guo PhD, Yongkang Zhang PhD, Meda E. Pavkov MD, Kai McKeever Bullard PhD, Hui Shao MD,Â
doi : 10.1111/dom.14894
To examine changes in racial and ethnic disparities in glucose-lowering drugs (GLD) use and glycated haemoglobin A1c in US adults with diabetes from 2005 to 2018.
Weight regain after behavioural weight management programmes and its impact on quality of life and cost effectiveness: Evidence synthesis and health economic analyses
Jamie Hartmann-Boyce DPhil, Linda J Cobiac PhD, Annika Theodoulou MClinSc, Jason L. Oke DPhil, Ailsa R Butler DPhil, Peter Scarborough DPhil, Anastasios Bastounis PhD, Anna Dunnigan MSc, Rimu Byadya MSc, F. D. Richard Hobbs FMedSci, Falko F. Sniehotta PhD, Ben Amies-Cull MBChB, Paul Aveyard PhD, Susan A. Jebb PhD,Â
doi : 10.1111/dom.14895
We used data from a recent systematic review to investigate weight regain after behavioural weight management programmes (BWMPs, sometimes referred to as lifestyle modification programmes) and its impact on quality-of-life and cost-effectiveness.
Eight-year trends in obesity-related complications and health care cost progression in a US population with obesity: A retrospective cohort study
Marc Evans MD, Vamshi Ruthwik Anupindi MS, Mitch DeKoven MHSA, Elisabeth de Laguiche MSc, Victoria Divino BA, Mads D. Faurby MSc, Christiane Lundegaard Haase PhD, Kasper Sommer Matthiessen MSc, Jonathan Pearson-Stuttard FRSPH,Â
doi : 10.1111/dom.14897
Obesity-related complications (ORCs) impose a substantial health burden on affected individuals, and economic costs to health care systems. We examined ORCs and the progression of direct health care costs over 8 years, stratified by obesity class.
Continuous glucose monitoring-based time-in-range using insulin glargine 300 units/ml versus insulin degludec 100 units/ml in type 1 diabetes: The head-to-head randomized controlled InRange trial
Tadej Battelino MD, Thomas Danne MD, Steve V. Edelman MD, Pratik Choudhary MD, Eric Renard MD, Jukka Westerbacka MD, Bhaswati Mukherjee MD, Valerie Pilorget MD, Mathieu Coudert MSc, Richard M. Bergenstal MD,Â
doi : 10.1111/dom.14898
To use continuous glucose monitoring (CGM)-based time-in-range (TIR) as a primary efficacy endpoint to compare the second-generation basal insulin (BI) analogues insulin glargine 300 U/ml (Gla-300) and insulin degludec 100 U/ml (IDeg-100) in adults with type 1 diabetes (T1D).
Glucagon induces the hepatic expression of inflammatory markers in vitro and in vivo
Francesco Andreozzi, Concetta Di Fatta, Rosangela Spiga, Gaia Chiara Mannino, Elettra Mancuso, Carolina Averta, Carmen De Caro, Martina Tallarico, Antonio Leo, Rita Citraro, Emilio Russo, Giovambattista De Sarro, Giorgio Sesti,Â
doi : 10.1111/dom.14902
Glucagon exerts multiple hepatic actions, including stimulation of glycogenolysis/gluconeogenesis. The liver plays a crucial role in chronic inflammation by synthesizing proinflammatory molecules, which are thought to contribute to insulin resistance and hyperglycaemia.
Comparative effects of weight loss and incretin-based therapies on vascular endothelial function, fibrinolysis and inflammation in individuals with obesity and prediabetes: A randomized controlled trial
Mona Mashayekhi, Joshua A. Beckman MD, MS, Hui Nian PhD, Erica M. Garner MD, Dustin Mayfield APRN, Jessica K. Devin, John R. Koethe MD, Jonathan D. Brown MD, Katherine N. Cahill MD, Chang Yu PhD, Heidi Silver Phd, Kevin Niswender, James M. Luther, Nancy J. Brown MD,Â
doi : 10.1111/dom.14903
To test the hypothesis that glucagon-like peptide-1 receptor (GLP-1R) agonists have beneficial effects on vascular endothelial function, fibrinolysis and inflammation through weight loss-independent mechanisms.
Challenging the 50-50 rule for the basal-bolus insulin ratio in patients with type 2 diabetes who maintain stable glycaemic control
Roy Harper MD, Eran Bashan PhD, Kevin J. Williams MD, Sajitha Sritharan, Mark Willis, Deanna J. Marriott PhD, Israel Hodish MD,Â
doi : 10.1111/dom.14904
For patients using basal-bolus insulin therapy, it is widespread clinical practice to aim for a 50-50 ratio between basal and total daily bolus. However, this practice was based on a small study of individuals without diabetes. To assess the rule in real-world practice, we retrospectively analyzed patients on basal-bolus therapy that was adjusted at least weekly by an artificial intelligence-driven titration within the d-Nav® Insulin Management Technology.
Associations of liver fat content with cardiometabolic phenotypes and outcomes in a multi-ethnic population: Results from the Dallas Heart Study
Minh-da Le MD, Yiling Wu MPH, Jarett D. Berry MD, Jeffrey D. Browning MD, James A. de Lemos MD, Ian J. Neeland MD, Ildiko Lingvay MD,Â
doi : 10.1111/dom.14905
To evaluate the associations between liver fat content and cardiometabolic parameters to explore potential threshold values that define metabolically healthy liver fat content, and to examine the association of liver fat content with cardiovascular events as well as its longitudinal progression.
Continuous glucose monitoring metrics (Mean Glucose, time above range and time in range) are superior to glycated haemoglobin for assessment of therapeutic efficacy
David Rodbard MD,Â
doi : 10.1111/dom.14906
To evaluate continuous glucose monitoring (CGM) metrics for use as alternatives to glycated haemoglobin (HbA1c) to evaluate therapeutic efficacy.
Incident heart failure, arrhythmias and cardiovascular outcomes with sodium-glucose cotransporter 2 (SGLT2) inhibitor use in patients with diabetes: Insights from a global federated electronic medical record database
Ameenathul Mazaya Fawzy MB, José Miguel Rivera-Caravaca PhD, Paula Underhill, Laurent Fauchier MD, Gregory Y. H. Lip MD,Â
doi : 10.1111/dom.14854
To investigate the impact of sodium-glucose cotransporter 2 (SGLT2) inhibitors on the risk of incident heart failure and adverse cardiovascular outcomes.
Ethnicity and risks of severe COVID-19 outcomes associated with glucose-lowering medications: A cohort study
Francesco Zaccardi PhD, Pui San Tan PhD, Carol Coupland PhD, Baiju R. Shah PhD, Ash Kieran Clift MBBS, Defne Saatci MBBS, Martina Patone PhD, Simon J. Griffin DM, Hajira Dambha-Miller PhD, Kamlesh Khunti PhD, Julia Hippisley-Cox FRCP,Â
doi : 10.1111/dom.14872
Racial, ethnic and sex disparities among participants in cardiovascular outcomes trials in type 2 diabetes: A systematic review and descriptive analysis
Ioannis Avgerinos MD, Thomas Karagiannis MD, Aris Liakos MD, Apostolos Tsapas MD, Eleni Bekiari MD,Â
doi : 10.1111/dom.14900
Testing for association between exonic glucagon-like peptide 1 receptor mutation with physical and brain health traits in UK Biobank
Joey Ward PhD, Laura M. Lyall PhD, Rona J. Strawbridge PhD, Ioana Stanciu MSc, Michele Veldsman PhD, Victoria Garfield PhD, Carlos Celis-Morales PhD, Danielle Newby PhD, William Stewart PhD, Jill P. Pell MD, Naveed Sattar MD, Donald M. Lyall PhD,Â
doi : 10.1111/dom.14879
Sodium-glucose cotransporter-2 inhibitor use was associated with lower risks of stroke and cardiac arrest but not ventricular arrhythmias?
Lixin Du, Jiao Qin, Yu Zhang,Â
doi : 10.1111/dom.14878
Response to letter from Du et al. regarding article ‘Sodium-glucose cotransporter-2 inhibitor use was associated with lower risks of stroke and cardiac arrest but not ventricular arrhythmias?’
Ameenathul Mazaya Fawzy MB, José Miguel Rivera-Caravaca PhD, Laurent Fauchier MD, Gregory Y. H. Lip MD,Â
doi : 10.1111/dom.14913
A simplified straightforward protocol for the use of U-500 regular insulin
Mayer B. Davidson MD,Â
doi : 10.1111/dom.14896
